Ibuprofen

證據等級: L5

預測適應症: 7 個

Ibuprofen: From NSAID Therapy to Acromesomelic Dysplasia, Hunter-Thompson Type

One-Sentence Summary

Ibuprofen is a widely used nonsteroidal anti-inflammatory drug (NSAID), though no Taiwan-specific approved indication text is available in this evidence pack. The TxGNN model's top prediction is Acromesomelic Dysplasia, Hunter-Thompson Type, a rare congenital skeletal disorder, but this candidate currently has 0 clinical trials and 0 publications supporting it, and the model's own rationale flags it as a likely embedding-clustering false positive.

Quick Overview

Item	Content
Original Indication	Not available — no `original_indications` or Taiwan license data in this evidence pack
Predicted New Indication	Acromesomelic Dysplasia, Hunter-Thompson Type
TxGNN Prediction Score	99.74%
Evidence Level	L5
Taiwan Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap, DG002). Ibuprofen is generally known as a propionic-acid-class NSAID that inhibits COX-1/COX-2 and prostaglandin synthesis, but no drug-specific MOA record was returned for this candidate.

Importantly, this prediction should not be treated as mechanistically well-supported. The model's own rationale for the top-ranked disease states that Acromesomelic Dysplasia, Hunter-Thompson Type is caused by GDF5 gene mutations — a congenital structural skeletal disorder with no known pathogenic overlap with the COX/prostaglandin-inhibition pathway that underlies ibuprofen's pharmacology. The evidence pack explicitly notes this high score is suspected to be a graph-embedding clustering false positive rather than a biologically grounded signal.

This pattern repeats across all seven ranked candidates in this pack: brachyolmia-amelogenesis imperfecta syndrome, myosclerosis, brachyolmia, brachydactyly-syndactyly syndrome, pseudoachondroplasia, and colobomatous microphthalmia-rhizomelic dysplasia syndrome are all rare congenital or developmental skeletal/connective-tissue disorders. Only pseudoachondroplasia's rationale notes a plausible (but purely symptomatic, non-disease-modifying) link — NSAID use for joint pain — while every other candidate is explicitly described as lacking a known inflammatory or mechanistic pathway connection to ibuprofen. None of the seven candidates has any supporting clinical trial or literature evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Taiwan Market Information

Ibuprofen currently has no marketing authorization in Taiwan (0 licenses on record; market status: Not marketed). No product name, dosage form, or approved indication text is available for this evidence pack.

Safety Considerations

Please refer to the package insert for safety information.

(Note: TFDA label warnings/contraindications are recorded as a Blocking data gap (DG001) — this is required before any S1 safety pre-assessment can proceed.)

Conclusion and Next Steps

Decision: Hold

Rationale: All seven TxGNN-predicted indications for ibuprofen are rare congenital skeletal/connective-tissue disorders with L5 evidence (score-only, no clinical trials or literature), and the top-ranked candidate's own mechanistic rationale flags it as a likely embedding-clustering false positive with no known pathogenic overlap with NSAID pharmacology. Combined with a Blocking gap on TFDA label data and a High-severity gap on MOA, this candidate cannot advance past S0.

To proceed, the following is needed:

TFDA label warnings/contraindications (DG001, Blocking) — required before any safety pre-assessment
DrugBank MOA data (DG002, High) to properly assess mechanistic plausibility
Independent biological/genetic rationale review to confirm or rule out the suspected embedding-clustering artifact before treating this prediction as a viable candidate
If pursuing further, re-run TxGNN ranking against non-rare-disease indication sets to check whether this candidate list reflects a systematic clustering issue specific to ibuprofen's embedding
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.